In particular, the SGLT2 inhibitor empagliflozin (Empa) has been shown to reduce cardiovascular mortality and nonfatal myocardial infarction, stroke, and cardiovascular death regardless of the presence of type 2 diabetes [13, 16–18]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.